|
4CPS-001 |
A REVISION OF PRESCRIBING PUMP INHIBITOR PRESCRIPTIONS IN INTERNAL MEDICINE AND ADDICTOLOGY DEPARTMENT |
|
4CPS-002 |
ANALYSIS AND IMPROVEMENT OF PROFESSIONNAL PRACTICES: PRESCRIPTION’S EVALUATION OF PROTON PUMP INHIBITORS IN ORAL ROUTES |
|
4CPS-003 |
AN EVALUATION OF GASTROINTESTINAL PROPHYLAXIS IN ELDERLY PATIENTS ON ASPIRIN THERAPY |
|
4CPS-004 |
PERTINENCE OF THE PRESCRIPTION OF STRESS ULCER PROPHYLAXIS IN INTENSIVE CARE MEDICINE |
|
4CPS-005 |
GLP-1 AGONIST LIRAGLUTIDE AS ADD-ON THERAPY IN TYPE 2 DIABETES |
|
4CPS-006 |
PHARMACIST-LED MEDICINE RECONCILIATION AT DIABETES OUTPATIENT CLINIC |
|
4CPS-007 |
COST MINIMISATION STUDY: SWITCH VIAL TO PEN IN GERIATRICS |
|
4CPS-008 |
IMPACT OF PHARMACEUTICAL INTERVIEW IN PATIENT ACCEPTANCE OF INSULIN GLARGINE’S BIOSIMILAR 100UI/ML |
|
4CPS-009 |
EVALUATION OF THE SAFETY OF INHIBITORS OF THE CO-TRANSPORTER 2 IN A UNIVERSITY CARE HOSPITAL |
|
4CPS-010 |
INSULIN PRESCRIPTION ANALYSIS IN A THIRD-LEVEL HOSPITAL |
|
4CPS-011 |
PREVALENCE AND RELATIONSHIP BETWEEN HYPOVITAMINOSIS D AND INSULIN RESISTANCE IN OBESE PATIENT CANDIDATES FOR BARIATRIC SURGERY |
|
4CPS-012 |
PREVALENCE OF NUTRITIONAL COMPLICATIONS ACCORDING TO THE REQUESTED HOSPITALISATION SERVICE OF TOTAL PARENTERAL NUTRITION |
|
4CPS-013 |
ORAL ANTICOAGULANT PRESCRIPTION PRACTICE AFTER AN ISCHAEMIC STROKE |
|
4CPS-014 |
ABSTRACT WITHDRAWN |
|
4CPS-015 |
EVALUATION OF ANTICOAGULANTS MISUSE IN PATIENTS ADMITTED FOR ISCHAEMIC STROKE IN A NEUROLOGY UNIT |
|
4CPS-016 |
ABSTRACT WITHDRAWN |
|
4CPS-017 |
EVALUATION OF PHARMACISTS' INPUT IN ANTICOAGULATION CLINIC REVIEWING DIRECT ORAL ANTICOAGULANTS INITIATED IN A SECONDARY CARE HOSPITAL IN LONDON |
|
4CPS-018 |
EVALUATION OF ANTIPLATELET AGENT PRESCRIBING IN PATIENTS ON DIRECT ORAL ANTICOAGULANT |
|
4CPS-019 |
MEDICATION USE EVALUATION OF EDOXABAN IN A TERTIARY HOSPITAL |
|
4CPS-020 |
ANTICOAGULATION THERAPY IN HAEMODIALYSIS - A CLINICAL PHARMACIST EXPERIENCE IN A PRIMARY CARE TEAM |
|
4CPS-021 |
ABSTRACT WITHDRAWN |
|
4CPS-022 |
HIGH INPUT IN PATIENT SAFETY - DOCUMENTATION OF CARDIOVASCULAR SYSTEM DRUGS |
|
4CPS-023 |
SACUBITRIL/VALSARTAN (ENTRESTO) IN REAL LIFE: AN OBSERVATIONAL STUDY IN A HOSPITAL CENTRE |
|
4CPS-024 |
EFFICACY, SAFETY AND ACCEPTANCE OF TREATMENT WITH ALIROCUMAB OR EVOLOCUMAB IN PATIENTS WITH DYSLIPIDAEMIA |
|
4CPS-025 |
LIPID MODIFICATION THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE |
|
4CPS-026 |
ADHERENCE AND EFFECTIVENESS OF PCSK9 INHIBITORS IN ROUTINE CLINICAL PRACTICE |
|
4CPS-027 |
REAL-WORLD EFFECTIVENESS OF EVOLOCUMAB AND ALIROCUMAB AT 12 MONTHS OF TREATMENT |
|
4CPS-028 |
STATIN OVERUSE? EVALUATION OF STATIN INITIATION FOR PRIMARY PREVENTION DURING HOSPITALISATION BETWEEN TWO NEIGHBOURING COUNTRIES IN EUROPE IN HIGH-RISK PATIENTS |
|
4CPS-029 |
CLINICAL EXPERIENCE OF NEW LIPID-LOWERING THERAPIES: EVOLOCUMAB AND ALIROCUMAB |
|
4CPS-030 |
ANALYSIS OF ADAPTATION TO A PROTOCOL OF USE OF THE PCSK9 INHIBITORS |
|
4CPS-031 |
THE PRIMARY EFFICACY ENDPOINT FOR ALIROCUMAB, REDUCTIONS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL |
|
4CPS-032 |
SKIN PROTECTION AND PREVENTION OF CUTANEOUS MYCOSIS |
|
4CPS-033 |
THE USE OF ORAL APREMILAST FOR THE TREATMENT OF PLAQUE PSORIASIS |
|
4CPS-034 |
USE OF USTEKINUMAB IN REFRACTORY PATIENTS OF PSORIASIS |
|
4CPS-035 |
PERSISTENCE AND SAFETY OF APREMILAST IN PSORIASIS |
|
4CPS-036 |
APREMILAST ADHERENCE IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS |
|
4CPS-037 |
THE IMPACT OF MULTIDISCIPLINARY COLLABORATION IN OPTIMISING THE PRESCRIPTION OF ANTIBIOTICS IN A PAEDIATRIC HOSPITAL |
|
4CPS-038 |
QUALITY OF LIFE OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS UNDERGOING OUT-PATIENT TREATMENT WITH DUPILUMAB |
|
4CPS-039 |
DUPILUMAB TREATMENT DISCONTINUATION DUE TO LIMITING ADVERSE EFFECTS: A CASE REPORT |
|
4CPS-040 |
OPTIMISING OF ANTIBIOTIC PROPHYLAXIS AT CARDIAC SURGERY CLINIC |
|
4CPS-041 |
IMPLEMENTATION OF AN EMPIRICAL ANTIBIOTIC TREATMENT GUIDE: IMPACT ON ANTIOBITIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT |
|
4CPS-042 |
SWITCH FROM CLARITHROMYCIN TO AZITHROMYCIN - ONE OPTION TO OPTIMISE MACROLIDE USE THROUGH CLINICAL PHARMACISTS |
|
4CPS-043 |
EXTENSIVELY PANDRUG-RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS: ANALYSIS AND OUTCOMES |
|
4CPS-044 |
IMPACT OF CLINICAL PHARMACIST-VANCOMYCIN MONITORING ON PATIENT SAFETY OUTCOME |
|
4CPS-045 |
VALUE OF THE CLINICAL PHARMACIST IN THE PHARMACOKINETIC MONITORING OF ANTIMICROBIALS: HEALTH OUTCOMES |
|
4CPS-046 |
PHARMACEUTICAL INTERVENTIONS IN ANTIMICROBIAL TREATMENT IN A 150-BED HOSPITAL |
|
4CPS-047 |
FEASIBILITY OF PHARMACY FOLLOW-UP OF ANTIBIOTIC RE-EVALUATION IN A UNIVERSITY HOSPITAL: DAY-2 OR/AND DAY-7? |
|
4CPS-048 |
QUALITY OF THE EMPIRIC ANTIBIOTIC TREATMENT IN COMMUNITY-ACQUIRED PNEUMONIA |
|
4CPS-049 |
CEFTOBIPROLE IN EMPIRICAL TREATMENT OF BONE AND JOINT INFECTIONS: SURVEY OF THE PRESCRIPTIONS, RESPECT OF THE PROTOCOL AND ECONOMIC EVALUATION OVER 6 MONTHS |
|
4CPS-050 |
ANALYSIS OF ANTIBIOTIC ADMINISTRATION IN SURGICAL PROPHYLAXIS |
|
4CPS-051 |
ABSTRACT WITHDRAWN |
|
4CPS-052 |
FROM THE SURVEILLANCE OF ANTIBIOTICS PRESCRIPTIONS TO LIMITATION OF MULTIDRUG RESISTANT BACTERIA STRAINS: THE ROLE OF THE HOSPITAL PHARMACY IN DEFINING A CARBAPENEM-SPARING-STRATEGY |
|
4CPS-053 |
STUDY ON DAPTOMYCIN USE AS A FIRST STEP TOWARDS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME |
|
4CPS-054 |
USE OF ANTIMICROBIAL AGENTS IN THE EMERGENCY DEPARTMENT IN A THIRD-LEVEL HOSPITAL |
|
4CPS-055 |
EFFICACY AND SAFETY OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF MALARIA |
|
4CPS-056 |
MAPPING ANTIBIOTIC USE PATTERNS IN A SEPTIC ORTHOPAEDIC WARD |
|
4CPS-057 |
HOW WELL IS THE TARGET CONCENTRATION OF VANCOMYCIN ACHIEVED IN INTENSIVE CARE UNIT PATIENTS? |
|
4CPS-058 |
AVOID SIMULTANEUS PRESCRIPTION BETWEEN LINEZOLID AND VORICONAZOLE: PHARMACOKINETIC STUDY |
|
4CPS-059 |
EFFECTIVENESS OF MEROPENEM TREATMENT IN CRITICAL PATIENTS: PHARMACOKINETIC STUDY |
|
4CPS-060 |
PREVALENCE OF VANCOMYCIN-RELATED NEUTROPAENIA, THROMBOCYTOPAENIA AND ACUTE KIDNEY INJURY |
|
4CPS-061 |
EXTENDED INFUSION OF MEROPENEM IN A NEONATE WITH COMPLICATED KLEBSIELLA PNEUMONIAE MENINGITIS |
|
4CPS-062 |
IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMME ON CARBAPENEMS RESISTANCE AND CONSUMPTION IN A TERTIARY HOSPITAL: A BEFORE-AND-AFTER INTERVENTIONAL STUDY |
|
4CPS-063 |
IMPACT OF PHARMACEUTICAL CARE IN THE RATIONAL USE OF DAPTOMYCIN |
|
4CPS-064 |
EVALUATION OF BROAD-SPECTRUM BETA-LACTAM PRESCRIPTIONS (EXCEPTCARBAPENEMS) IN THE MILITARY HOSPITAL OF INSTRUCTION MOHAMMED V RABAT |
|
4CPS-065 |
CLINICAL IMPACT EVALUATION OF IMPLEMENTING ANTIBIOTHERAPY CONTROL OF MORE THAN 7 DAYS |
|
4CPS-066 |
ADHERENCE OF PATIENTS RECEIVING ANTIBIOTIC THERAPY AFTER HOSPITALISATION |
|
4CPS-067 |
EFFECTIVENESS AND SAFETY OF THE EARLY SWITCH FROM INTRAVENOUS TO ORAL ANTIBIOTICS TREATMENT IN THE PNEUMOLOGY WARD |
|
4CPS-068 |
IMPACT OF THE PHARMACEUTICAL RECOMMENDATIONS FOR THE IMPROVEMENT IN ANTIBIOTICS PRESCRIPTION |
|
4CPS-069 |
IMPACT OF IMPLEMENTING A GLOBAL COLLABORATIVE PHYSICIAN-PHARMACIST STRATEGY ON PROPHYLACTIC ANTIBIOTIC PRACTICES IN A UNIVERSITY HOSPITAL CENTRE |
|
4CPS-070 |
DOES ANTIBIOTIC CONSUMPTION PREDICT THE INCIDENCE DENSITY OF HEALTHCARE-ASSOCIATED INFECTIONS? |
|
4CPS-071 |
SHORTAGE OF DRUGS ERA: IMPACT OF PIPERACILIN/TAZOBACTAM SHORTAGE |
|
4CPS-072 |
ABSTRACT WITHDRAWN |
|
4CPS-073 |
FOLLOW-UP OF RECOMMENDATIONS ON DOSE ADJUSTMENT OF CEFTOLOZANE/TAZOBACTAM IN RENAL FAILURE |
|
4CPS-074 |
ROLE OF THE PHARMACIST IN THE EVALUATION OF THE PRESCRIPTIVE APPROPRIATENESS IN ANTIBIOTIC THERAPY AS A “SINGLE DOSE” |
|
4CPS-075 |
CREATION OF AN INNOVATIVE AND ATTRACTIVE TRAINING PROGRAMME FOR PRESCRIBERS TO PROMOTE THE CORRECT USE OF FLUOROQUINOLONES |
|
4CPS-076 |
ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND |
|
4CPS-077 |
INHALED COLISTIN AS CHRONIC SUPPRESSOR THERAPY IN PATIENTS WITH BRONCHIECTASIAS WITH NON-CYSTIC FIBROSIS |
|
4CPS-078 |
ADEQUACY OF SYSTEMATIC ANTIFUNGAL AGENT PRESCRIPTIONS IN A TEACHING HOSPITAL |
|
4CPS-079 |
PATIENT WITH COMPLICATED FUNGAL ENDOCARDITIS : A CASE REPORT |
|
4CPS-080 |
APPROPRIATE USE OF ANTIFUNGALS: IMPACT OF AN ANTIFUNGAL STEWARDSHIP PROGRAMME ON THE CLINICAL OUTCOME OF CANDIDAEMIA IN A UNIVERSITY HOSPITAL |
|
4CPS-081 |
EVALUATION OF THE STANDARD DOSAGE REGIMEN OF VORICONAZOLE IN A PAEDIATRIC AND ADULT POPULATION THROUGH THERAPEUTIC DRUG MONITORING |
|
4CPS-082 |
NEPHROGENIC DIABETES INSIPIDUS INDUCED BY LIPOSOMAL AMPHOTERICIN B: A CASE REPORT |
|
4CPS-083 |
AGING WITH HIV: OPTIMISING PHARMACOTHERAPY BEYOND INTERACTIONS |
|
4CPS-084 |
EVOLUTION OF NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS USE SINCE 2010 IN A THIRD-LEVEL HOSPITAL |
|
4CPS-085 |
STEWARDSHIPS OF HEPATITIS C VIRUS PATIENTS IN PRISONS |
|
4CPS-086 |
A FULLY INTEGRATED CLINICAL TRIAL-LIKE SYSTEM TO MANAGE AND MONITOR PERSISTENCE IN PLANNED HEPATITIS C TREATMENT |
|
4CPS-087 |
EVOLUTION OVER TIME OF ANTIRETROVIRALS |
|
4CPS-088 |
EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C |
|
4CPS-089 |
RETREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION AFTER VIROLOGICAL FAILURE TO DIRECT-ACTING ANTIVIRALS |
|
4CPS-090 |
HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND F0-F1 LIVER FIBROSIS STAGE |
|
4CPS-091 |
CURRENT STATE OF RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHOM PRIOR THERAPY FAILED IN A HEPATITIS REFERRAL CENTRE |
|
4CPS-092 |
PREVALENCE OF POLYPHARMACY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION |
|
4CPS-093 |
PERSISTENCE OF AN ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN A TERTIARY LEVEL HOSPITAL |
|
4CPS-094 |
EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR IN REAL-WORLD CLINICAL PRACTICE FOR CHRONIC HEPATITIS C INFECTION |
|
4CPS-095 |
RESCUE OF PATIENTS INFECTED WITH HEPATITIS C VIRUS NOT RESPONDING TO INTERFERON-FREE THERAPIES |
|
4CPS-096 |
ABSTRACT WITHDRAWN |
|
4CPS-097 |
COBICISTAT INTERACTIONS WITH CHRONIC TREATMENTS |
|
4CPS-098 |
INFLUENCE OF PHARMACOLOGICAL INTERACTIONS IN HEPATITIS C TREATMENT SELECTION IN OPIATE-DEPENDENT PATIENTS |
|
4CPS-099 |
PALIVIZUMAB OFF LABEL USE IN TERTIARY REFERRAL HOSPITAL |
|
4CPS-100 |
QUALITY OF INTRATECT: IN VITRO EVALUATION OF BIOLOGICAL ACTIVITIES |
|
4CPS-101 |
INTRAVENOUS IMMUNOGLOBULINS USE FOR CHILDREN'S NEUROLOGICAL AND NEURODEVELOPMENTAL DISORDERS |
|
4CPS-102 |
MEASUREMENT OF HEALTH OUTCOMES OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE COMBINATION IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA |
|
4CPS-103 |
EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA |
|
4CPS-104 |
CHEMOTHERAPY TREATMENT IN COLORECTAL CANCER PATIENTS OLDER THAN 70 YEARS AT A TERTIARY HOSPITAL |
|
4CPS-105 |
PRESCRIBED ANTINEOPLASTIC AGENTS IN PAEDIATRIC PATIENTS |
|
4CPS-106 |
MULTI-STATE MODEL TO ESTIMATE THE OPTIMAL DURATION OF FIRST-LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: DATA FROM THE NATIONAL REGISTRY AGAMENON |
|
4CPS-107 |
EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN THE SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER |
|
4CPS-108 |
DABRAFENIB AND TRAMETINIB: COMBINATION THERAPY FOR METASTATIC MELANOMA |
|
4CPS-109 |
POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA TREATED AT A UNIVERSITY HOSPITAL |
|
4CPS-110 |
SAFETY AND EFFECTIVENESS OF OBINUTUZUMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: OUR EXPERIENCE |
|
4CPS-111 |
TREATMENT OF FOLLICULAR LYMPHOMA IN ROUTINE CLINICAL PRACTICE. |
|
4CPS-112 |
ASSESSMENT OF AGGRESSIVE CARE IN ONCOLOGY PATIENTS AT THE END OF LIFE IN CLINICAL PRACTICE |
|
4CPS-113 |
DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS |
|
4CPS-114 |
DOSING OF PLATINUM AND TAXANES IN OBESE PATIENTS: A SYSTEMATIC REVIEW |
|
4CPS-115 |
RITUXIMAB IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS |
|
4CPS-116 |
VEMURAFENIB-INDUCED STEVENS-JOHNSON SYNDROME IN A PATIENT WITH METASTATIC MELANOMA: A CASE REPORT |
|
4CPS-117 |
DOSE BANDING - OPTIMISING DOSES IN CETUXIMAB OR BEVACIZUMAB REGIMENS |
|
4CPS-118 |
EXPERIENCE OF DUAL TARGETING USE OF NEOADJUVANT HER2-POSITIVE BREAST CANCER |
|
4CPS-119 |
EXPERIENCE OF NAB-PACLITAXEL AND GEMCITABINE USE IN METASTATIC PANCREATIC CANCER |
|
4CPS-120 |
ERLOTINIB IN NON-SMALL-CELL LUNG CANCER WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS |
|
4CPS-121 |
COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPY OF ANTINEUTROPHIL CYTOPLASM ANTIBODY-ASSOCIATED VASCULITIDES |
|
4CPS-122 |
EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE |
|
4CPS-123 |
EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE |
|
4CPS-124 |
SAFETY AND EFFECTIVENESS OF TRASTUZUMAB EMTANSIN IN LOCALLY ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER |
|
4CPS-125 |
TOLERANCE TO CHEMORADIOTHERAPY TREATMENT: COMPARING CAPECITABINE WITH 5-FLUOROURACIL IN NEOADJUVANT THERAPY FOR STAGE II-III RECTAL CANCER |
|
4CPS-126 |
EFFECTIVENESS AND SAFETY OF NAB-PACLITAXEL IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN A REAL-WORLD SETTING |
|
4CPS-127 |
DEVELOPMENT OF A STRATIFICATION MODEL FOR AMBULATORY ONCOLOGY PHARMACY PATIENTS |
|
4CPS-128 |
ADEQUACY OF NIVOLUMAB AND PEMBROLIZUMAB IN NON-SMALL-CELL LUNG CANCER |
|
4CPS-129 |
CHEMOTHERAPY NEAR THE END OF LIFE IN ONCO-HAEMATOLOGICAL ADULT PATIENTS |
|
4CPS-130 |
PALBOCICLIB COMBINED WITH HORMONAL THERAPY FOR METASTATIC BREAST CANCER TREATMENT |
|
4CPS-131 |
RUXOLITINIB AS SALVAGE THERAPY IN PAEDIATRIAC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE |
|
4CPS-132 |
INTERACTIONS BETWEEN ALTERNATIVE THERAPIES AND PRODUCTS IN CLINICAL TRIAL IN ONCO-HAEMATOLOGY |
|
4CPS-133 |
DARATUMUMAB (DARZALEX) FOR THE TREATMENT OF MULTIPLE MYELOMA IN A THIRD-LEVEL HOSPITAL: VARIABILITY OF USE AND EFFECTIVENESS |
|
4CPS-134 |
HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH DISEASE-MODIFYING THERAPIES |
|
4CPS-135 |
TERIFLUNOMIDE AND DIMETHYLFUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS |
|
4CPS-136 |
ANALYSIS OF THE USE OF OMALIZUMAB IN ORAL TOLERANCE INDUCTION FOR HIGH-RISK FOOD ALLERGIES IN CHILDREN |
|
4CPS-137 |
NATALIZUMAB: A REVIEW OF ITS USE IN THE MANAGEMENT OF MULTIPLE SCLEROSIS, EXPERIENCE IN A UNIVERSITY HOSPITAL |
|
4CPS-138 |
BIOSIMILARS' UTILISATION UNDER HOSPITAL PHARMACY MANAGEMENT POLICY |
|
4CPS-139 |
THE PIRAMID STUDY: PATIENTS TREATED BY MYELOMA ORAL MEDICATION HAVE A BAD COMPLIANCE |
|
4CPS-140 |
HOW PHARMACISTS CAN IMPROVE PATIENTS' CARE MANAGEMENT IN SUBCUTANEOUS ANTIPSORIATIC BIOLOGIC THERAPY |
|
4CPS-141 |
ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS |
|
4CPS-142 |
ADJUVANT CHEMOTHERAPY AND RELAPSE-ASSOCIATED PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER |
|
4CPS-143 |
EVALUATION OF KNOWLEDGE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY THE REFERENCE PRODUCT CONCERNING BIOSIMILARS: ROLE OF CLINICAL PHARMACISTS |
|
4CPS-144 |
ESTABLISHMENT OF A PHARMACEUTICAL STANDARDISED INTERVIEW CONCERNING BIOSIMILARS OF INFLIXIMAB IN THE DAYCARE CLINIC OF A GASTROENTEROLOGY DEPARTMENT FOR PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE |
|
4CPS-145 |
PHARMACOGENETICS AS A TOOL IN DOSE ADJUSTMENT OF IMMUNOSUPPRESSIVE DRUGS: A CASE REPORT |
|
4CPS-146 |
SUBLINGUAL AND ENTERIC TACROLIMUS WHOLE BLOOD LEVELS IN AN INTENSIVE CARE UNIT |
|
4CPS-147 |
CLINICAL EXPERIENCE OF OPTIMISING CO-ADMINISTRATION THERAPY OF LOW-DOSE ALLOPURINOL WITH LOW-DOSE THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS ATTENDING A VIRTUAL PHARMACIST CLINIC |
|
4CPS-148 |
ANALYSIS OF INTRA-PATIENT VARIABILITY OF PLASMATIC LEVELS OF TACROLIMUS IN EARLY MAINTENANCE OF RENAL POST-TRANSPLANT |
|
4CPS-149 |
EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN THE DIFFERENT PERIODS OF THE KIDNEY POST-TRANSPLANT |
|
4CPS-150 |
EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN DIFFERENT PERIODS AFTER LIVER TRANSPLANT |
|
4CPS-151 |
INFLUENCE OF THE ROUTE AND PHARMACEUTICAL PREPARATION IN INTRA-PATIENT VARIABILITY OF TACROLIMUS SERUM LEVELS IN THE LIVER TRANSPLANT PATIENT |
|
4CPS-152 |
CHEMOTHERAPY PHARMACEUTICAL CONSULTATION: PHARMACEUTICAL INTERVENTIONS AFTER 18 MONTHS OF IMPLEMENTATION |
|
4CPS-153 |
COMPARATIVE ANALYSIS BETWEEN ORIGINATOR AND BIOSIMILAR INFLIXIMAB ACCORDING TO TROUGH LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
|
4CPS-154 |
ABSTRACT WITHDRAWN |
|
4CPS-155 |
A NEW MULTIDISCIPLINARY MODEL WITH THE CLINICAL PHARMACIST FOR MEDICATION RECONCILIATION IN THE PATIENT WITH ADVANCED RENAL DISEASE |
|
4CPS-156 |
SAFETY PROFILE OF APREMILAST IN PSORIASIS AND PSORIATIC ARTHRITIS |
|
4CPS-157 |
TUMOUR NECROSIS FACTOR INHIBITORS: UTILITY OF PHARMACOKINETICS MONITORING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT |
|
4CPS-158 |
CLINICAL BENEFIT OF INFLIXIMAB MONITORING IN INFLAMMATORY BOWEL DISEASE |
|
4CPS-159 |
PERIOPERATIVE MANAGEMENT OF ANTIRHEUMATIC MEDICATION IN REAL PRACTICE: IS MISMANAGEMENT RELATED TO POST-SURGICAL COMPLICATIONS? |
|
4CPS-160 |
EFFICACY AND SAFETY OF ANAKINRA AND CANAKINUMAB FOR THE TREATMENT OF IL-36R ANTAGONIST DEFICIENCY |
|
4CPS-161 |
SCOPING REVIEW ON THE USE OF CANAKINUMAB AND ANAKINRA IN INTERLEUKIN-1 ANTAGONIST RECEPTOR DEFICIENCY |
|
4CPS-162 |
MEDICATION COUNSELLING BY CLINICAL PHARMACISTS IN NEWLY GRAFTED RENAL TRANSPLANT RECIPIENTS |
|
4CPS-163 |
BONE METASTASIS TREATMENT IN PROSTATE CANCER: EFFICACY AND SAFETY |
|
4CPS-164 |
ORAL KETAMINE IN UNMANAGEABLE CHRONIC PAIN: A CASE REPORT |
|
4CPS-165 |
LIDOCAINE 5% PLASTER: IS IT WORTH THE PAIN? |
|
4CPS-166 |
IS THERE STILL A PLACE FOR CHLORAL HYDRATE SYRUP IN HOSPITAL? |
|
4CPS-167 |
STUDY OF THE USE OF TAPENTADOL |
|
4CPS-168 |
POSTOPERATIVE PAIN MANAGEMENT AND PAIN REFERRED BY ADULT PATIENTS 24 HOURS AFTER SURGERY AND ONE MONTH AFTER DISCHARGE |
|
4CPS-169 |
COMPARATIVE ANALYSIS OF EFFECTIVENESS BETWEEN A PATIENT-CONTROLLED ANALGESIA MORPHINE DEVICE AND A SUBLINGUAL SUFENTANIL TABLET SYSTEM |
|
4CPS-170 |
ESTIMATING THE ECONOMIC IMPACT OF PHARMACIST-LED PRESCRIPTION ORDER VALIDATION OF OPIOID PRESCRIPTIONS IN A TERTIARY UNIVERSITY HOSPITAL |
|
4CPS-171 |
THE CHOICE OF ANTIEPILEPTIC DRUG TREATMENT AFTER STATUS EPILEPTICUS |
|
4CPS-172 |
IMPACT OF MEDICATION RECONCILIATION IN PATIENTS ON ADMISSION TO AN EXPERT CENTRE FOR PARKINSON'S DISEASE |
|
4CPS-173 |
8 YEARS' EVOLUTION OF ANTIPSYCHOTICS PRESCRIPTIONS IN A MENTAL HEALTH PUBLIC INSTITUTION |
|
4CPS-174 |
A NEW BREATH FOR CLOZAPINE … |
|
4CPS-175 |
OPTIMISATION OF ANTIPSYCHOTIC TREATMENT IN A PATIENT UNDERGOING DIALYSIS: A CASE REPORT |
|
4CPS-176 |
A SYSTEMATIC REVIEW OF META-ANALYSES OF THE EFFICACY OF ORAL ANTIPSYCHOTIC LURASIDONE FOR THE TREATMENT OF ADULT PATIENTS WITH SCHIZOPHRENIAA SYSTEMATIC REVIEW OF META-ANALYSES OF THE EFFICACY OF ORAL ANTIPSYCHOTIC LURASIDONE FOR THE TREATMENT OF ADULT PA |
|
4CPS-177 |
DEALING WITH IATROGENIC CARDIAC ARREST IN PSYCHIATRY, DO NOT OVERLOOK MONITORING! |
|
4CPS-178 |
ABSTRACT WITHDRAWN |
|
4CPS-179 |
USE OF SPECIFIC DRUGS FOR DEMENTIA IN PEOPLE AT THE END OF LIFE IN NURSING HOMES |
|
4CPS-180 |
THE PRACTICE OF USING DEXMEDETOMIDINE IN A PAEDIATRIC INTENSIVE CARE UNIT: RETROSPECTIVE CHART REVIEW |
|
4CPS-181 |
EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN CHRONIC IDIOPATHIC URTICARIA |
|
4CPS-182 |
EXPERIENCE WITH OMALIZUMAB IN THE TREATMENT OF UNCONTROLLED PERSISTENT ASTHMA |
|
4CPS-183 |
COLLABORATION WITH THE OPHTHALMOLOGY SERVICE IN A PUBLIC RESIDENTIAL CARE HOME |
|
4CPS-184 |
OFF-LABEL USES OF BEVACIZUMAB IN OPHTHALMOLOGY IN A MOROCCAN UNIVERSITY HOSPITAL |
|
4CPS-185 |
THE EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY IN THE MANAGEMENT OF GAUCHER DISEASE |
|
4CPS-186 |
THERAPEUTIC DRUG MONITORING OF TYROSINE KINASE INHIBITORS: KEY TO PERSONALISED MEDICINE IN ONCOLOGY |
|
4CPS-187 |
EVALUATION OF EXIT PRESCRIPTIONS USING COMPUTERISED PROVIDER ORDER-ENTRY SYSTEM FOR OUTPATIENTS |
|
4CPS-188 |
GALENIC PREPARATIONS AND RARE DISEASES: GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY: EXPERIENCE IN A LOCAL HOSPITAL |
|
4CPS-189 |
ADEQUACY OF THE PRESCRIPTION OF PARENTERAL NUTRITION IN NEONATOLOGY |
|
4CPS-190 |
RITUXIMAB USE IN CHILDREN, A SINGLE HOSPITAL EXPERIENCE |
|
4CPS-191 |
EFFECTIVENESS AND SAFETY OF RADIUM-223 CHLORIDE IN BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
|
4CPS-192 |
IDENTIFYING MEDICATION HISTORY ERRORS AT HOSPITAL ADMISSION USING THE LUND INTEGRATED MEDICINES MANAGEMENT MODEL |
|
4CPS-193 |
A THEORETICALLY BASED CROSS-SECTIONAL SURVEY ON THE BEHAVIOURS AND EXPERIENCES OF CLINICAL PHARMACISTS CARING FOR CHRONIC KIDNEY DISEASE PATIENTS |
|
4CPS-194 |
CLINICAL IMPACT OF GENOMIC BIOMARKERS PREDICTORS OF RESPONSE AND THE THERAPEUTIC STRATEGY IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL |
|
4CPS-195 |
PHARMACIST INTERVENTIONS: THE SUCCESS OF AN ANTIMICROBIAL STEWARDSHIP TEAM |
|
4CPS-196 |
ABSTRACT WITHDRAWN |
|
4CPS-197 |
DETERMINING THE NECESSARY COMPONENTS OF A PHARMACEUTICAL CARE COMPLEXITY SCREENING TOOL: AN e-DELPHI STUDY |
|
4CPS-198 |
CLINICAL EXPERIENCE WITH DALBAVANCIN IN A TERTIARY HOSPITAL |
|
4CPS-199 |
ASSESSMENT OF MEDICATION RECONCILIATION IN CHRONIC COMPLEX PATIENTS |
|
4CPS-200 |
USE OF PROHEMOSTATIC DRUGS IN MASSIVE HAEMORRHAGE EPISODES |
|
4CPS-201 |
ACCULTURATION OF PRESCRIBERS TO RECOMMENDATIONS ON THE MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS TWO YEARS' AFTER AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A UNIVERSITY HOSPITAL |
|
4CPS-202 |
ANTICHOLINERGICAL RISK IN CHRONIC COMPLEX PATIENTS |
|
4CPS-203 |
PHARMACOECONOMIC ANALYSIS OF THE MANAGEMENT OF GAUCHER DISEASE IN A PAEDIATRICS HOSPITAL |
|
4CPS-204 |
MEDICATION RECONCILIATION AND PHARMACOTHERAPEUTIC REVIEW IN AN ORTHOGERIATRIC UNIT OF A CENTRAL HOSPITAL |
|
4CPS-205 |
ENOXAPARIN DOSE ADJUSTMENT IN THE ELDERLY - THE INTERVENTION OF THE CLINICAL PHARMACIST |
|
4CPS-206 |
IMPACT OF PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION |
|
4CPS-207 |
SCREENING FOR PAINFUL DIABETIC NEUROPATHY |
|
4CPS-208 |
CHOOSING THE RIGHT WOUND DRESSING FOR THE RIGHT PRESSURE ULCER: THE DEVELOPMENT OF A COLOUR-BASED CHART HELPING HEALTHCARE PROVIDERS |
|
4CPS-209 |
OUTCOMES RESEARCH ON NEW TYROSINE KINASE INHIBITORS FOR NON-SMALL CELL LUNG CANCER |
|
4CPS-210 |
PATIENTS IN CLINICAL TRIALS AND THEIR TREATMENT: DID THE PRESCRIPTION SUPPORT A FIRST-LINE INFORMATION TOOL? |
|
4CPS-211 |
IMPACT OF THE ELECTRONIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT |
|
4CPS-212 |
PRESCRIPTION AND ADMINISTRATION OF ORAL MEDICATION THROUGH THE JEJUNOSTOMY AND THE NASOGASTRIC TUBE IN AN INTENSIVE CARE UNIT: IMPACT OF GOOD PRACTICES GUIDELINES ON CLINICAL PRACTICE |
|
4CPS-213 |
ABSTRACT WITHDRAWN |
|
4CPS-214 |
ASSESSMENT OF THE MEDICATION ERROR RATE PRE-PRESCRIPTION DURING THE MEDICATION RECONCILIATION PROCESS |
|
4CPS-215 |
ACCESS TO ‘FONDO AIFA 5%’ AS AN INSTRUMENT SUPPORTING THE SUSTAINABILITY IN A SHARED CLINICAL MANAGEMENT OF RARE AND DIFFICULT-TO-TREAT DISEASES |
|
4CPS-216 |
PRESCRIPTION OF FALL-RISK-INCREASING DRUGS IN PATIENTS SUFFERING A FALL WITH MAJOR LESIONS DURING ADMISSION AT AN INTERMEDIATE CARE CENTRE |
|
4CPS-217 |
ASSESSING MEDICATION ADHERENCE AND CONDITION-RELATED KNOWLEDGE OF HEART FAILURE PATIENTS |
|
4CPS-218 |
ASSESSMENT OF CLINICAL PHARMACIST INTERVENTIONS IN AN INTENSIVE CARE UNIT |
|
4CPS-219 |
ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN AN EMERGENCY DEPARTMENT |
|
4CPS-220 |
THERAPEUTIC DRUG MONITORING: ARE WE GETTING IT RIGHT AND OPTIMISING THERAPY? |
|
4CPS-221 |
IMPACT OF HOSPITAL-CITY COMMUNICATION BASED ON THE MULTIPROFESSIONAL AND COLLABORATIVE DEVELOPMENT OF THE DISCHARGE LETTER ON THE CONTINUITY OF PATIENTS' MEDICATION MANAGEMENT-CITY STUDY |
|
4CPS-222 |
IMPACT OF THE ESTABLISHMENT OF THE ASSISTED ELECTRONIC PRESCRIPTION ON THE IMPROVEMENT OF THE UNIT-DOSE DRUG DISPENSATION SYSTEM |
|
4CPS-223 |
ANTICOAGULANT THERAPY IN CHRONIC COMPLEX PATIENTS WITH ATRIAL FIBRILLATION |
|
4CPS-224 |
EVALUATION OF SYSTEMIC ANTIBIOTICS AND ANTIFUNGAL USE IN AN INTENSIVE PAEDIATRIC CARE UNIT : A FIVE-YEARS STUDY IN A FRENCH UNIVERSITY HOSPITAL |
|
4CPS-225 |
THE ROLE OF CLINICAL PHARMACISTS MONITORING REGARDING THE EFFECTIVENESS AND TOLERANCE OF EXPENSIVE DRUGS PRESCRIBED OFF-LABEL |
|
4CPS-226 |
ADHERENCE TO TREATMENT IN OLDER ADULTS ADMITTED TO AN ACUTE GERIATRIC UNIT AND ASSOCIATED FACTORS |
|
4CPS-227 |
EVALUATION OF ADHERENCE TO INHALED MEDICATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
|
4CPS-228 |
AN EVALUATION OF A PHARMACIST-MANAGED PAEDIATRIC TOXICOLOGY CONSULTATION SERVICE |
|
4CPS-229 |
CLINICAL MANAGEMENT OF MALIGNANT MESOTHELIOMA IN AN ASBESTOS-ENDEMIC AREA |
|
4CPS-230 |
ABSTRACT WITHDRAWN |
|
4CPS-231 |
ABSTRACT WITHDRAWN |
|
4CPS-232 |
REORGANISATION IN HOSPITAL OUTPATIENT DRUG DELIVERY: ANY PROGRESS? |
|
4CPS-233 |
ANALYSIS OF DRUG PRESCRIPTIONS OF INCOMPATIBLE DRUGS THROUGH DRUG UTILISATION REVIEW |
|
4CPS-234 |
PHARMACIST INTERVENTIONS IN NEONATAL INTENSIVE CARE UNIT AND ASSOCIATED COST AVOIDANCE AND COST SAVINGS |
|
4CPS-235 |
PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS AS AN EARLY-ONSET ADVERSE EFFECT IN ADULT PATIENTS |
|
4CPS-236 |
THE IMPACT OF A WARD-BASED PHARMACY TECHNICIAN SERVICE |
|
4CPS-237 |
STUDY OF PATIENT SATISFACTION WITH PHARMACEUTICAL INTERVIEW IN AN OUTPATIENT ONCOLOGY MEDICAL UNIT |
|
4CPS-238 |
MEDICATION AND CONFUSION IN ACUTE HOSPITAL OLDER PATIENTS |
|
4CPS-239 |
A COMPARISON OF CLINICAL PHARMACY ACTIVITY BETWEEN TWO METHODS OF CLINICAL PHARMACY SERVICE DELIVERY IN AN ACUTE PSYCHIATRIC HOSPITAL |
|
4CPS-240 |
A QUALITATIVE STUDY ON HOW CLINICAL PHARMACISTS PREFORM MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT |
|
4CPS-241 |
DDI-PREDICTOR: A NOVEL CLINICAL PHARMACY DECISION-MAKING TOOL FOR DOSE ADAPTATION? |
|
4CPS-242 |
REGULATORY VALIDATION OF PRESCRIPTIONS AT A TEACHING HOSPITAL |
|
4CPS-243 |
EFFECTIVENESS AND USE OF OFF-LABEL TREATMENTS IN A GENERAL HOSPITAL |
|
4CPS-244 |
TIME TO PERFORM MEDICATION RECONCILIATION AT ADMISSION IN A NEUROLOGY UNIT: COMPARISON BETWEEN PROACTIVE AND RETROACTIVE PROCESSES |
|
4CPS-245 |
EVALUATION OF THE DEGREE OF ADHERENCE TO THE INTRAVENOUS TREATMENT OF AMBULATORY PATIENTS |
|
4CPS-246 |
PALATABILITY ASSESSMENT OF ORAL MEDICATION |
|
4CPS-247 |
LOCAL ASSESSMENT OF THE IMPACT OF PHARMACIST-LED MEDICATION RECONCILIATION ON HOSPITALISED ELDERLY PATIENTS |
|
4CPS-248 |
ANTIMICROBIAL POINT PREVALENCE SURVEY |
|
4CPS-249 |
IMPLEMENTATION OF AN INTEGRATED SOFTWARE FOR CLINICAL TRIALS MANAGEMENT AND AUTOMATED PREPARATION OF INVESTIGATIONAL DRUGS IN A HOSPITAL PHARMACY |
|
4CPS-250 |
INFLUENCE OF TIME AND STORAGE CONDITIONS IN THE STABILITY OF NEONATAL TOTAL PARENTERAL NUTRITION ADMIXTURES |
|
4CPS-251 |
IMPACT OF A MULTIDISCIPLINARY TEAM IN REDUCING POLYPHARMACY AND TREATMENT COMPLEXITY IN HOME CARE PATIENTS |
|
4CPS-252 |
ABSTRACT WITHDRAWN |
|
4CPS-253 |
COMMUNITY PHARMACY-BASED eGFR SCREENING FOR EARLY DETECTION OF CHRONIC KIDNEY DISEASE IN HIGH-RISK PATIENTS |
|
4CPS-254 |
BIOSIMILAR RITUXIMAB - A YEAR BEYOND |
|
4CPS-255 |
THE EFFECT OF AN ENHANCING MEDICATION ADHERENCE PROGRAMME FOR A TYPE 2 DIABETES MELLITUS NETWORK |
|
4CPS-256 |
LINEZOLID USAGE AND COST ANALYSISAFTER A HOSPITAL TRANSFER |
|
4CPS-257 |
DETERMINING FACTORS AFFECTING PATIENTS’ CLARITY ON DISPENSED MEDICATION INSTRUCTIONS: A CASE STUDY AT COPPERBELT UNIVERSITY HEALTH FACILITY IN KITWE, ZAMBIA |
|
4CPS-258 |
IMPACT OF A TEAM OF CLINICAL PHARMACISTS IN A PAEDIATRIC SURGERY UNIT: RESULTS AFTER 6 MONTHS |
|
4CPS-259 |
EVALUATION OF PATIENTS', DOCTORS' AND COMMUNITY PHARMACISTS' SATISFACTION CONCERNING PHARMACEUTICAL CONSULTATIONS FOR PATIENTS RECEIVING ORAL ANTI-CANCER DRUGS |
|
4CPS-260 |
PRE-ANAESTHESIA BEST POSSIBLE MEDICATION HISTORY FOR ORTHOPAEDIC SURGERY-PROGRAMMED PATIENTS |
|
4CPS-261 |
ANALYSIS OF THE METHODOLOGY TO COMMUNICATE POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN INPATIENTS TO AN INTERNAL MEDICINE SERVICE OF A THIRD-LEVEL HOSPITAL |
|
4CPS-262 |
PLACE OF CLINICAL PHARMACIST IN THE MANAGEMENT OF PATIENTS UNDERGOING BARIATRIC SURGERY |
|
4CPS-263 |
ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS CARRIED OUT IN AN INTENSIVE CARE UNIT |
|
4CPS-264 |
ANALYSIS OF THE DISCREPANCIES FOUND IN THE RECONCILIATION OF CONCOMITANT MEDICATION IN A COHORT OF ELDERLY PATIENTS INFECTED WITH HIV |
|
4CPS-265 |
EFFECT OF DEDICATED PHARMACIST INTERVENTION IN NEUROCRITICAL CARE UNIT: BEFORE AND AFTER PARTICIPATING IN MULTIDISCIPLINARY ROUNDS |
|
4CPS-266 |
Clone of ANALYSIS OF AN EPIDEMIOLOGICAL MODEL FOR THE TREATMENT OF HEPATITIS C VIRUS IN CO-INFECTED HIV/HCV DRUG ADDICTIONS VIA PARENTERAL |
|
4CPS-266 |
ANALYSIS OF AN EPIDEMIOLOGICAL MODEL FOR THE TREATMENT OF HEPATITIS C VIRUS IN CO-INFECTED HIV/HCV DRUG ADDICTIONS VIA PARENTERAL |
|
4CPS-267 |
LACK OF HEPATITIS C VIRUS UPTAKE IN HIV/HCV CO-INFECTED PATIENTS |
|
4CPS-268 |
EVALUATION OF THE SATISFACTION OF THE IMPLEMENTATION OF A PHARMACEUTICAL LETTER OF HOSPITAL DISCHARGE TRANSMITTED TO PATIENTS AND COMMUNITY HEALTH PROFESSIONALS |
|
4CPS-269 |
ARE PATIENTS AND HEALTHCARE PROFESSIONALS WILLING TO EXCHANGE ON THE PRICE OF TREATMENTS TO CHOOSE A BIOSIMILAR? EXPERIENCE BASED ON THE DELPHI METHOD |
|
4CPS-270 |
A SIMULATION PILOT STUDY OF HEALTH OPTIMISATION FOR PATIENTS WITH BIPOLAR DISORDERS: AN EMERGING ROLE FOR CLINICAL PHARMACISTS AS DECISION COACHES |
|
4CPS-271 |
DEVELOPMENT OF PHARMACIST MEDICATION REVIEW IN PAEDIATRIC DISCHARGE PROCESS |
|
4CPS-272 |
ANALYSIS OF ADVERSE REACTION REPORTS BEFORE AND AFTER THE USE OF EQUIVALENT IMATINIB IN A TERTIARY HOSPITAL |
|
4CPS-273 |
PHARMACY INTERVENTION AND DRUG PRESCRIPTION REGULATIONS IN A TERTIARY HOSPITAL |
|
4CPS-274 |
ABSTRACT WITHDRAWN |
|
4CPS-275 |
A SYSTEMATIC REVIEW OF PHARMACIST INPUT IN THE SCREENING, MANAGEMENT AND PREVENTION OF METABOLIC SYNDROME |
|
4CPS-276 |
ANTIMICROBIAL STEWARDSHIP PROGRAMME IMPLEMENTATION IN THE GULF COOPERATION COUNCIL STATES: A SYSTEMATIC REVIEW |
|
4CPS-277 |
ABSTRACT WITHDRAWN |
|
4CPS-278 |
ABSTRACT WITHDRAWN |
|
4CPS-279 |
THE EFFECT OF CONTINUATION OF HOME MEDICATION BY HOSPITALISED PATIENTS ON MEDICATION WASTE AND PATIENT SATISFACTION, A MULTICENTRE, QUASI-EXPERIMENTAL STUDY WITH A PRE-POST DESIGN |
|
4CPS-280 |
DOES PLATELET-RICH PLASMA COMPOSITION MATTER IN HIP OSTEOARTHRITIS? |
|
4CPS-281 |
A COMPARATIVE STUDY OF THE SATISFACTION OF CLIENTS WITH THE SERVICES OF AN OUTPATIENT PHARMACY IN A TERTIARY HOSPITAL |
|
4CPS-282 |
ABSTRACT WITHDRAWN |
|
4CPS-283 |
ABSTRACT WITHDRAWN |
|
4CPS-284 |
BINARY LOGISTIC REGRESSION ANALYSIS TO EVALUATE THE INFLUENCE OF DIFFERENT BASAL FACTORS ON THE EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR |